Study Evaluating CMC-544 Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Sponsor(s)

Wyeth Pharmaceuticals

Principal Investigator(s)Jonathan L Kaufman, MD
Dates11/21/2007 - 12/31/2013